Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques

Table 1 Patient characteristics for all patients, and subgroups of local, locoregional, and metastatic recurrence

	All patients^a		Local recurrence^b		Locoregional recurrence^c		Metastatic disease^d
							Regional nodal and metastatic lesions		Metastatic lesions alone
	n = 32	%	n = 7	%	n = 8	%	n = 13	%	n = 4	%
Median age at diagnosis	56.5 (range 52.5–73.7)		55.0 (range 53.0–61.5)		57.2 (range 53.1–69.4)		59.2 (range 53.0–73.7)		58.6 (range 52.5–66.8)
Tumor stage
T2	14	43.8%	5	62.5%	3	37.5%	3	23.1%	3	75.0%
T3a	8	25.0%	1	12.5%	4	50.0%	3	23.1%	0	0%
T3b	9	28.1%	1	12.5%	1	12.5%	6	46.2%	1	25.0%
T4	1	3.1%	0	0.0%	0	0.0%	1	7.7%	0	0%
Nodal stage
N0	26	81.3%	6	75.0%	7	87.5%	10	76.9%	3	75.0%
N1	1	3.1%	0	0.0%	0	0.0%	1	7.7%	0	0%
Nx	5	15.6%	1	12.5%	1	12.5%	2	15.4%	1	25.0%
Gleason score
6	2	6.3%	2	25.0%	0	0.0%	0	0%	0	0%
7 (3 + 4)	8	25.0%	2	25.0%	3	37.5%	1	7.7%	2	50.0%
7 (4 + 3)	11	34.4%	2	25.0%	1	12.5%	8	61.5%	0	0%
8	8	25.0%	1	12.5%	2	25.0%	4	30.8%	1	25.0%
9	3	9.4%	0	0.0%	2	25.0%	0	0%	1	25.0%
Positive surgical margins	13	40.6%	3	37.5%	3	37.5%	7	53.8%	0	0%
Median time to biochemical failure	30.1 mo (1.1–113.9)		30.5 mo (1.4–86.3)		27 mo (2.7–113.9)		15.8 mo (1.1–82.0)		49.9 mo (1.4–94.3)
Median PSA at ¹⁸F-PSMA PET	2.4 ng/mL (0.38–22.37)		1.3 ng/ml (0.5–3.3)		1.6 ng/ml (0.4–8.9)		4.8 ng/ml (1.3–22.4)		5.4 ng/ml (2.0–7.9)

^aAll 32 patients included in the analysis of those who received PORT after prostatectomy prior to mpMRI and PSMA PET/CT imaging as per inclusion criteria
^bSubgroup of the 32 patients with local recurrence alone on mpMRI and PSMA PET/CT
^cSubgroup of the 32 patients who were found to have regional nodal recurrence (± local) on mpMRI and PSMA PET/CT
^dSubgroup of the 32 patients who were found to have metastatic (± local or regional nodal) disease on mpMRI and PSMA PET/CT

ISSN: 1748-717X